1. Market Research
  2. > Oxagen Limited – Product Pipeline Review – 2013

Oxagen Limited – Product Pipeline Review – 2013

  • May 2013
  • -
  • Global Markets Direct
  • -
  • 27 pages

Oxagen Limited – Product Pipeline Review – 2013

Summary

Global Market Direct’s pharmaceuticals report, “Oxagen Limited - Product Pipeline Review - 2013” provides data on the Oxagen Limited’s research and development focus. The report includes information on current developmental pipeline, complete with latest updates, and features on discontinued and dormant projects.

This report is built using data and information sourced from Global Markets Direct’s proprietary databases, Oxagen Limited’s corporate website, SEC filings, investor presentations and featured press releases, both from Oxagen Limited and industry-specific third party sources, put together by Global Markets Direct’s team.

Scope

- Oxagen Limited - Brief Oxagen Limited overview including business description, key information and facts, and its locations and subsidiaries.
- Review of current pipeline of Oxagen Limited human therapeutic division.
- Overview of pipeline therapeutics across various therapy areas.
- Coverage of current pipeline molecules in various stages of drug development, including the combination treatment modalities, across the globe.
- Product profiles for late stage and clinical stage products of Oxagen Limited with complete description of the product’s developmental history, mechanism of action, therapeutic class, target and major milestones.
- Recent updates of the Oxagen Limited’s pipeline in the last quarter.
- Key discontinued and dormant projects.
- Latest news and deals relating to the products.

Reasons to buy

- Evaluate Oxagen Limited’s strategic position with total access to detailed information on its product pipeline.
- Assess the growth potential of Oxagen Limited in its therapy areas of focus.
- Identify new drug targets and therapeutic classes in the Oxagen Limited’s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas.
- Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps.
- Exploit collaboration and partnership opportunities with Oxagen Limited.
- Avoid Intellectual Property Rights related issues.
- Explore the dormant and discontinued projects of Oxagen Limited and identify potential opportunities in those areas.

Table Of Contents

Oxagen Limited - Product Pipeline Review - 2013
Table of Contents

Table of Contents 2
List of Tables 3
List of Figures 3
Oxagen Limited Snapshot 4
Oxagen Limited Overview 4
Key Information 4
Key Facts 4
Oxagen Limited - Research and Development Overview 5
Key Therapeutic Areas 5
Oxagen Limited - Pipeline Review 7
Pipeline Products by Stage of Development 7
Pipeline Products - Monotherapy 8
Oxagen Limited - Pipeline Products Glance 9
Oxagen Limited Clinical Stage Pipeline Products 9
Phase II Products/Combination Treatment Modalities 9
Oxagen Limited - Early Stage Pipeline Products 10
Pre-Clinical Products/Combination Treatment Modalities 10
Oxagen Limited - Drug Profiles 11
CRTH2 Antagonist Programme 11
Product Description 11
Mechanism of Action 11
RandD Progress 11
OC-000459 12
Product Description 12
Mechanism of Action 12
RandD Progress 12
OC-002417 14
Product Description 14
Mechanism of Action 14
RandD Progress 14
OC-2125 15
Product Description 15
Mechanism of Action 15
RandD Progress 15
OC-2184 16
Product Description 16
Mechanism of Action 16
RandD Progress 16
OC-499 17
Product Description 17
Mechanism of Action 17
RandD Progress 17
Oxagen Limited - Pipeline Products by Route of Administration 18
Oxagen Limited - Pipeline Products By Mechanism of Action 19
Oxagen Limited - Dormant Projects 20
Oxagen Limited - Locations And Subsidiaries 21
Head Office 21
Financial Deals Landscape 22
Oxagen Limited, Deals Summary 22
Oxagen Limited, Pharmaceuticals and Healthcare, Deal Details 23
Venture Financing 23
Oxagen Raises US$33 Million In Series C Financing 23
Appendix 26
Methodology 26
Coverage 26
Secondary Research 26
Primary Research 26
Expert Panel Validation 26
Contact Us 27
Disclaimer 27



List of Tables

Oxagen Limited, Key Information 4
Oxagen Limited, Key Facts 4
Oxagen Limited - Pipeline by Indication, 2013 6
Oxagen Limited - Pipeline by Stage of Development, 2013 7
Oxagen Limited - Monotherapy Products in Pipeline, 2013 8
Oxagen Limited - Phase II, 2013 9
Oxagen Limited - Pre-Clinical, 2013 10
Oxagen Limited - Pipeline By Route of Administration, 2013 18
Oxagen Limited - Pipeline Products By Mechanism of Action, 2013 19
Oxagen Limited - Dormant Developmental Projects,2013 20
Oxagen Limited, Deals Summary 22
Oxagen Raises US$33 Million In Series C Financing 23



List of Figures

Oxagen Limited - Pipeline by Indication, 2013 6
Oxagen Limited - Pipeline by Stage of Development, 2013 7
Oxagen Limited - Monotherapy Products in Pipeline, 2013 8
Oxagen Limited - Pipeline By Route of Administration, 2013 18
Oxagen Limited - Pipeline Products By Mechanism of Action, 2013 19

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Veronica

+1 718 514 2762

ref:plp2013

Reportlinker.com © Copyright 2016. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.